Quince Therapeutics
QNCX
81 hedge funds and large institutions have $715M invested in Quince Therapeutics in 2020 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 42 increasing their positions, 10 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
320% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 10
37% more capital invested
Capital invested by funds: $523M → $715M (+$192M)
29% more funds holding
Funds holding: 63 → 81 (+18)
0.07% more ownership
Funds ownership: 0.19% → 0.26% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$85.3M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$36.5M |
| 3 |
BlackRock
New York
|
+$11.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.9M |
| 5 |
ECG
EPIQ Capital Group
San Francisco,
California
|
+$6.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.14M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$659K |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
-$394K |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$284K |
| 5 |
N
Natixis
Paris,
France
|
-$202K |
QNCX Hedge Fund Activity: Q2 2020 in Review
81 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q2 2020, worth a combined $715M — up 37% from $523M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new QNCX positions and 4 closed out — a net gain of 18 holders — while 42 added to existing stakes and 10 trimmed.
The largest buyer was Capital World Investors, adding an estimated $85.3M. The largest seller was Ikarian Capital, exiting entirely with an estimated $1.14M sold.
- 81 institutional investors held Quince Therapeutics (QNCX) as of Q2 2020, up from 63 in Q1 2020.
- Funds reported $715M of Quince Therapeutics stock for Q2 2020, up 37% quarter-over-quarter.
- 22 funds opened new Quince Therapeutics positions in Q2 2020 and 4 closed out, a net change of +18 holders.
- The largest Quince Therapeutics buyer in Q2 2020 was Capital World Investors, an estimated $85.3M added.
- The largest Quince Therapeutics seller in Q2 2020 was Ikarian Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2020.